Eastman Chemical to Launch Optifilm Additive at European Coatings Show

Eastman Chemical has expanded its architectural paint portfolio with the introduction of Eastman Optifilm additive OT1200. The product will be launched at the European Coatings Show to be conducted in Nürnberg, Germany from 29 to 31 March 2011.

The OT1200 additive makes formulators to decrease the content of volatile organic compounds in water-based wall or trim paints by substituting volatile glycols. It enhances both wet edge and open time and retains other characteristics of the paints.

The additive functions well at different application conditions and allows architectural paint formulators to make products that perform well and comply with strict regulatory standards. Eastman Chemical has been offering a broad range of additives and coalescents to the coatings market for over four decades.

Growth Platform Leader of Eastman Chemical, Jennifer Cogar commented that the market demand for enhanced open time is huge in the European and North American region and thus there is an increase in the production of paints with lower volatile organic compounds. The OT120 makes formulators to produce paints that have enhanced aesthetics and performance properties.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Eastman. (2019, February 09). Eastman Chemical to Launch Optifilm Additive at European Coatings Show. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=28507.

  • MLA

    Eastman. "Eastman Chemical to Launch Optifilm Additive at European Coatings Show". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=28507>.

  • Chicago

    Eastman. "Eastman Chemical to Launch Optifilm Additive at European Coatings Show". AZoM. https://www.azom.com/news.aspx?newsID=28507. (accessed November 21, 2024).

  • Harvard

    Eastman. 2019. Eastman Chemical to Launch Optifilm Additive at European Coatings Show. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=28507.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.